Policy / Pricing The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs Drug ChannelsBy Adam J.Read full story pharminent June 2, 2026 (Last updated: June 4, 2026) Drug Channels By Adam J. Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ASCO ’26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancerNext: Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb Related Stories Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026 Policy / Pricing UK commits to pharma IP protection in Swiss trade deal pharminent July 16, 2026 Policy / Pricing Germany approves healthcare costs overhaul despite significant pharma opposition pharminent July 13, 2026
